Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research
08 mars 2022 16h35 HE
|
Affimed N.V.
In a Clinical Trials Plenary Session an update of the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13 in patients with CD30-positive...
Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing
09 févr. 2022 16h05 HE
|
Affimed N.V.
Precomplexing NK cells with Innate Cell Engagers (ICE® molecules) results in a CAR-like NK cell product, whose magnitude and specificity of antibody-dependent cellular cytotoxicity (ADCC) remain...
Affimed to Present at Upcoming Investor Events
08 févr. 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update
06 janv. 2022 06h30 HE
|
Affimed N.V.
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose...
Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition
13 déc. 2021 09h05 HE
|
Affimed N.V.
AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeysPre-complexing...
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13
09 déc. 2021 06h30 HE
|
Affimed N.V.
For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional patient...
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab
08 déc. 2021 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas
22 nov. 2021 07h11 HE
|
Affimed N.V.
100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cord...
Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing
12 nov. 2021 07h01 HE
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...